Skip to content

Welcome

Celebrating Over 80 Years Of Service!

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Advance the comprehensive management of allergy and inflammatory disease in Otolaryngology-Head and Neck Surgery through training, education, and advocacy."

AAOA Member Benefits

  • Up to 60% discount for CME programs and free Annual Meeting. All AAOA’s CME programs meet ABOTOHNS Continuing Certification.
  • AAOA US ENT Affinity program, where AAOA members can gain savings on antigen, allergy supplies, and any of the other 5 service lines US ENT offers. For more email info@usentpartners.com.
  • Tools and resources to comply with US General Chapter 797 and practice management tools.
  • Advocacy support.
  • And much more! Learn More

ADVOCACY UPDATES

Your AAOA at the AMA

I want to urge you to consider membership in the AMA because your membership in…

Read more

Fall Advocacy Update: USP 797, E/M Documentation and Payment

Revisions to USP Chapter 797 Open for Comment Since the United States Pharmacopeia (USP) released…

Read more

Brief Update on the Final CY 2019 Physician Fee Schedule

On November 1, the Centers for Medicare and Medicaid Services released the final Physician Fee…

Read more

Upcoming Dates

04/01/24: Fellow Exam Application Deadline
Learn more

06/01/24: Research Grant Cycle
Learn more

06/25/24: Membership Application Deadline to be eligible for AAOA Member rate for the 2024 Basic Course

08/02/24: Scientific Abstract Submission Deadline
Learn more

12/01/24: Research Grant Cycle
Learn more

EDUCATION

AAOA Advanced Course

The recorded course content is available until April 30, 2024. This year’s Advanced Course featured Laryngology and Skull Base Surgery with Nausheen Jamal, MD and Garret Choby, MD as featured faculty.

RESIDENTS

For information about Resident membership, opportunities, DosedDaily, research grants, and other resources. Learn More

IFAR

Available Now

aaoaf-ifar

IFAR Impact Factor: 2.454

IFAR Featured Content: COVID-19 - Free Access
Endonasal instrumentation and aerosolization risk in the era of COVID‐19: simulation, literature review, and proposed mitigation strategies . Read More

Changes in Managing Practices

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2024 AAOA Advanced Course in Allergy & Immunology - Hybrid
On-Demand Content Access Deadline:
April 30, 2024
Learn More and Register

2024 AAOA Basic Course in Allergy & Immunology - Hybrid
July 25-27, 2024
The Diplomat, Hollywood, Florida
Learn More and Register

2024 AAOA Annual Meeting - Hybrid
November 8-10, 2024
Four Seasons Hotel Las Vegas
Learn More 

USP 797 Online Module
Learn More and Register

AAOA Educational Stacks
Next Availability - April 1, 2024

News and Updates

A Message From The AAOA President Michael Platt, MD, FAAOA

Read more

United Agrees To Give Physicians ERISA Rights in Connection with Repayment Demands

Bottom line Recent class action settlement gives all out-of-network (“ONET”) physicians important – and often overlooked –…

Read more
College Allergy Symptoms Treatment Back to Shcool

PRACTICE RESOURCES

AAOA Practice Resource Tool Kit

The American Academy of Otolaryngic Allergy (AAOA) Practice Resource Tool Kit is intended as a guide to help AAOA members integrate allergy into their otolaryngology practice and to continually improve on this integration as new information, regulations, and resources become available.

Read More

PARTNER RESOURCE CENTER

AAOA has launched a Partner Resource Center to bring you partner resources that can assist your practice and patient care.

Visit the New Center>

PATIENT CORNER

Congress Moves Closer to Close the Books on FY 2018 Appropriations

In a span of 4 days, Congress passed legislation to fund the government through March 23 and the President released his FY 2019 budget proposal.  The release of the President’s budget request signals the official start of the FY 2019 appropriations cycle, but Congress now has until March 23 to finish the FY 2018 process.

The Bipartisan Budget Act of 2018 had three important pieces: it ended the government’s funding through March 23, raised the budget caps for FY 2018 and 2019, and addressed many important health provisions.  Of note, the legislation included several technical corrections to the Medicare Access and CHIP Reauthorization Act (MACRA) that the American Medical Association (AMA) supported.  The Quality Payment Program authorized by MACRA is beginning its second year, but there were several issues that the Centers for Medicare and Medicaid Services (CMS) could not address without statutory changes.  Last week Congress took action and made the following changes to the program:

  • Part B drug costs are now excluded from the calculation of Merit-Based Incentive Payment System (MIPS) bonuses and penalties. They had been excluded from the CMS quality programs that pre-dated MACRA.
  • The MACRA statute required the cost performance category, one of the four MIPS performance categories, to be weighted at 30% of a provider’s score in year 3 of the program. However, cost measures are not ready for adoption for many specialties.  The legislation provides that for years 2 through 5 of the program the cost performance category shall count for no less than 10% and no more than 30% of the MIPS score, providing CMS with additional flexibility in the implementation of the program.
  • For years 1 and 2 of MACRA, CMS set the performance threshold, which determines if a physician will receive no adjustment, a bonus, or a penalty, relatively low. MACRA required that in year 3 the performance threshold be set at the mean or median of MIPS scores.  This legislation provides CMS with more flexibility in setting the threshold, requiring only that the performance threshold increase from year 3 to year 5 of MIPS.
  • MACRA authorized the Physician Focused Payment Model Technical Advisory Committee (PTAC) to review proposals for physician-focused alternative payment models and make recommendations on their implementation to CMS. This law expands PTAC’s scope, allowing the panel to provide initial feedback and an explanation for the feedback on models.

Also of note, the legislation repealed the Independent Payment Advisory Board (IPAB) that was originally authorized by the Affordable Care Act.  The IPAB which was never empaneled was charged with making recommendations to reduce Medicare spending if growth hit a designated threshold.  There was bipartisan opposition to IPAB because the board would have had the power to implement cuts to the Medicare program if Congress did not act.

Many provisions in the bill, like the funding extension for the Community Health Centers and the National Health Service Corps, included spending that had to be offset.  To help defray these costs, Congress reduced the physician fee schedule conversion factor in 2019 from 0.5 to 0.25 percent.  This replaced the extension of the misvalued code target, which had been included as an offset in the original House bill.  The AMA estimated an extension of the misvalued code target would have reduced the conversion factor by 0.45 percent.

On February 12, President Trump released his proposed budget for Fiscal Year 2019 (FY19).  While Congress will ultimately decide what funding levels programs receive through its annual appropriations process, the budget does highlight top-level priorities of the Administration.  These priorities include funding to address the opioid epidemic, an emphasis on regulatory restructuring and reorganizing, and policies to address drug pricing.

The President recommended a $473 million increase for the Food and Drug Administration (FDA) with some of the funding targeted at speeding the generic drug approval process and combating the opioid epidemic.  The budget proposal also includes $33.8 billion in funding to the National Institutes of Health (NIH), which is an increase of $747 million.  But, since the NIH budget includes $750 million in new funding to address the opioids epidemic and $730 million associated with moving a handful of agencies from other HHS departments to the NIH, in reality, most Institutes and Centers within the NIH would face cuts.

Back To Top